Rani Therapeutics Holdings, Inc. (NASDAQ:RANI – Get Free Report) CEO Talat Imran acquired 35,000 shares of the stock in a transaction on Friday, July 17th. The shares were purchased at an average cost of $0.72 per share, with a total value of $25,200.00. Following the transaction, the chief executive officer directly owned 469,736 shares of the company’s stock, valued at approximately $338,209.92. This trade represents a 8.05% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Rani Therapeutics Price Performance
Rani Therapeutics stock opened at $0.84 on Thursday. Rani Therapeutics Holdings, Inc. has a one year low of $0.44 and a one year high of $3.87. The business’s fifty day moving average is $0.80 and its 200 day moving average is $1.02. The stock has a market capitalization of $104.54 million, a PE ratio of -2.06 and a beta of 0.78.
Rani Therapeutics (NASDAQ:RANI – Get Free Report) last issued its earnings results on Friday, May 15th. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.02. The business had revenue of $1.71 million during the quarter, compared to analysts’ expectations of $1.12 million. As a group, sell-side analysts expect that Rani Therapeutics Holdings, Inc. will post -0.17 EPS for the current fiscal year.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
A number of research analysts recently weighed in on RANI shares. Wall Street Zen upgraded shares of Rani Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, May 17th. Weiss Ratings lowered shares of Rani Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 17th. Lake Street Capital initiated coverage on Rani Therapeutics in a report on Tuesday, April 14th. They set a “buy” rating and a $9.00 price target on the stock. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $5.00 price target on shares of Rani Therapeutics in a research note on Wednesday, May 20th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Rani Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $8.75.
Read Our Latest Research Report on Rani Therapeutics
Rani Therapeutics Company Profile
Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies for large-molecule drugs. The company’s proprietary RaniPill platform is designed to enable the gastrointestinal delivery of biologic therapies traditionally administered via injection. Through a swallowable capsule that autonomously deploys a microscopic injector in the small intestine, Rani aims to improve patient convenience and adherence for peptide and protein therapies, including insulin and other hormones.
Since its founding in 2012, Rani Therapeutics has advanced its lead programs through early-phase clinical trials, demonstrating proof-of-concept for oral insulin delivery.
Featured Articles
- Five stocks we like better than Rani Therapeutics
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for Rani Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rani Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
